| Item Type | Name |
|
Concept
|
Clinical Trials, Phase III as Topic
|
|
Concept
|
Clinical Trials, Phase I as Topic
|
|
Concept
|
Clinical Trials, Phase II as Topic
|
|
Academic Article
|
The role of maintenance therapy and novel taxanes in ovarian cancer.
|
|
Academic Article
|
Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.
|
|
Academic Article
|
Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy.
|
|
Academic Article
|
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
|
|
Academic Article
|
Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience.
|
|
Academic Article
|
Contemporary use of bevacizumab in ovarian cancer.
|
|
Academic Article
|
Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
|
|
Academic Article
|
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
|
|
Academic Article
|
A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer.
|
|
Academic Article
|
Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
|
|
Academic Article
|
Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.
|
|
Academic Article
|
Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.
|
|
Academic Article
|
Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug.
|
|
Academic Article
|
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
|
|
Academic Article
|
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
|
|
Academic Article
|
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
|
|
Academic Article
|
Phase III trials in ovarian cancer: The evolving landscape of front line therapy.
|
|
Academic Article
|
TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.
|
|
Academic Article
|
Emerging serine-threonine kinase inhibitors for treating ovarian cancer.
|
|
Academic Article
|
Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors.
|
|
Academic Article
|
European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies.
|
|
Academic Article
|
Bevacizumab (Avastin?) in cancer treatment: A review of 15?years of clinical experience and future outlook.
|
|
Academic Article
|
Executive summary of the American Radium Society? Appropriate Use Criteria for management of uterine carcinosarcoma.
|
|
Academic Article
|
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
|
|
Academic Article
|
Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
|
|
Academic Article
|
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
|
|
Academic Article
|
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
|
|
Academic Article
|
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
|
|
Academic Article
|
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
|
|
Academic Article
|
Tisotumab vedotin in recurrent or metastatic cervical cancer.
|
|
Academic Article
|
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
|